Highlights
About
Treatments for Autoimmune Diseases
XTL Biopharmaceuticals focuses on the acquisition and development of late-stage pharmaceutical product candidates for the treatment of unmet clinical needs. The company has three product candidates in clinical development. XTLs hCDR1 peptide is a compound that works via a novel mechanism for the treatment of systemic lupus erythematosus (SLE). hCDR1 has completed three clinical trials involving more than 400 patients. Recombinant erythropoietin is a compound being developed by XTL with the potential to help advanced-stage multiple myeloma patients live longer with a better quality of life. The companys SAM-101 is a proprietary combination of antipsychotic drugs and a known medicinal compound for the treatment of psychotic diseases, with a focus on schizophrenia. SAM-101 has completed a phase 2a study in accordance with the Helsinki guidelines at the Shalvata Medical Center.
Identity
| Name | XTL Biopharmaceuticals |
|---|---|
| Slug | xtl-biopharmaceuticals |
| Type / kind | startup |
| Crunchbase ID | xtl-biopharmaceuticals-ltd |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgJ6E-44LDA |
Status
| Status | active |
|---|---|
| Status reason | Public on TASE on Sep 2000;Public on NASDAQ on Sep 2005; |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Ra'anana |
| HQ address | HaHaroshet St 5, Ra'anana, Israel |
Web & social
Classifications
Funding
| Total raised | $30.0M |
|---|---|
| Current stage | Public |
| Market cap | $6.1M |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}